/ /

Ilana Cass, MD
Dr. Cass is an Assistant Professor of Obstetrics and Gynecology, UCLA/Cedars-Sinai Medical Center, Los Angeles, Calif.
Hormonal contraception and breast cancer: Is there a link?
Results of a prospective cohort study by Danish investigators suggest that current or recent use of hormonal contraceptives may be associated with an increased risk of breast cancer. Plus, Editorial Board Member, Ilana Cass, MD, weighs in on the impact of the study's findings.
Breast cancer screening and prevention: Results that matter
Randomized controlled trials have established that mammography reduces breast cancer mortality. However, mammography is less effective in women with dense breasts.
Cervical cancer screening and prevention 2016
Expert commentary on Practice Bulletin No. 157: Cervical Cancer Screening and Prevention
Why are ob/gyns burning out?
Issues with work-life balance, reimbursement, and time are contributors.
Update on BRCA and ovarian cancer
What are the current recommendations for managing women who are BRCA 1 or 2 carriers?
Surgical options for reducing risk in BRCA mutation carriers
Surgical options for reducing risk in BRCA mutation carriers
Among BRCA mutation carriers, risk-reducing bilateral salpingo-oophorectomy (RRSO) results in an 80% reduction in risk of ovarian cancer and a 50% reduction in risk of breast cancer if the surgery is performed before the onset of menopause.
Commentary: Recent updates on power morcellator debate
On November 25, the Food and Drug Agency (FDA) issued a warning against the use of laparoscopic power morcellators in the management of many women undergoing hysterectomy or myomectomy.
BRCA1 and BRCA2: Genetic testing and intervention strategies
Who should undergo genetic testing? Before ordering it, three conditions should be met: There should be a greater than 10% likelihood of a positive test; the ordering physician should be able to interpret the result; and the information should be used to make management decisions.